European Psychiatry - Volume 33 - March 2016

313 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S309
EW 550
Time to relapse monotherapy and
acquisition in a sample of
schizophrenic patients over 3 years of
follow-up
P. González Rivera ∗, A.J. Benito Ruiz , J. Prados Gomez ,
A. Hidalgo Borreguero , M. Soto Laguna , K. Preckler Pe˜na ,
S. Bola˜no Mendoza , F.J. González Díaz , V. González Rivera ,
M. Fernando-Torija Daza
1 Hospital Provincial de la Misericordia, Psiquiatria, Toledo, Spain
2 USMIJ, Psiquiatria, Toledo, Spain
3 Hospital Virgen del Prado, Psiquiatria, Talavera, Spain
4 Hospital 12 de Octubre, Psiquiatria, Madrid, Spain
5 Hospital Virgen de la Salud, Psiquiatria, Toledo, Spain
6 Hospital Sant Joan de Deu, Psiquiatria, Lleida, Spain
∗ Corresponding author.
Introduction Poor adherence to treatment is one of the main
problems in health care to psychiatric patients. The second-
generation antipsychotics, and the subsequent emergence of the
depot forms (long acting formulations) have facilitated this aspect,
increasing the time to clinical relapse in patients with schizophre-
nia.
Goals Determine the time to relapse in a clinical sample of
patients diagnosed with schizophrenia treated with paliperidone
palmitate over 3 years. Other objectives include the possible reduc-
tion in hospital admissions, as well as the possible reduction
of psychiatric emergency visits, concomitant medication (ben-
zodiazepines and Biperiden) and the possible increase in drug
monotherapy.
Methodology This is a study with a sample of 101 patients with
schizophrenia who had started treatment with PP (consecutive
sampling). Quantified variables in the 12 months prior to the
change of PP treatment with variables at 6, 12, 24 and 36 months
after initiation of treatment with PP were compared.
Results and conclusions At the end of the tracking, 72.22% (73
patients) remained clinically stable, with adequate adherence to
treatment and there have been no clinical relapses. It has obtained a
statistically significant reduction in the use of concomitant medica-
tion, emergency room visits and the average duration of revenues,
with no clinical relapse should occur in patients of the sample in
the second and third year.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW551
Effects of nicotine abstinence on
clinical symptoms. Study at 3 and
6-months follow-up of outpatients
with schizophrenia
P.A. Sáiz Martinez ∗, S. Al-Halabí , S. Fernández-Artamendi ,
L. García-Álvarez , E. Díaz-Mesa , E. Martínez-Santamaría ,
G. Florez , M. Arrojo , M.P. García-Portilla , J. Bobes
1 Universidad de Oviedo, Área de Psiquiatría - CIBERSAM, Oviedo,
Spain
2 Centro de Investigación Biomédica en Red de Salud Mental-
CIBERSAM., Área de Psiquiatría - Universidad de Oviedo, Oviedo,
Spain
3 Universidad de Oviedo, Facultad de Psicología, Oviedo, Spain
4 Centro Asistencial “AS Burgas”, Unidad de Conductas Adictivas -
Hospital Santa María Nai, Orense, Spain
5 Hospital Santa María Nai, Unidad de Conductas Adictivas, Orense,
Spain
6 Complejo Hospitalario Universitario de Santiago, Psiquiatría,
Santiago de Compostela, Spain
∗ Corresponding author.
Introduction Tobacco use has been associated with more
excitement and agitation symptoms, greater severity of global psy-
chopathology as measured by the Clinical General Impression (CGI)
Scale, and psychotic symptoms in patients with schizophrenia.
Aim To assess the effects of nicotine abstinence versus nicotine
maintenance on the clinical symptoms of a sample of outpatients
smokers diagnosed with schizophrenia.
Methods Sample: 81 outpatients with schizophrenia [72.8%
males; mean age (SD) = 43.35 (8.82)] currently smoking tobacco
[no. of cigarettes (SD) = 27.96 (12.29)]. Desing: non-randomized,
open-label, 6-month follow-up and multi-center study conducted
at 3 sites in Spain (Oviedo, Santiago de Compostela and Orense).
Instruments: Positive and Negative Syndrome Scale (PANSS), Clin-
ical Global Impression for Schizophrenia (CGI-SCH), Hamilton
Depression Rating Scale (HDRS). Antropometric measures: Body
mass index (BMI) and waist circumference. Vital sings: heart rate.
Procedure: Patients were assigned to 2 conditions:
– control group = patients continuing their tobacco use;
– experimental group = patients participated in vareniclina or nico-
tine patches treatment for smoking cessation.
Patients were evaluated at baseline (all patients smoking) and after
3 and 6 months.
Results No significant differences ( P>.05) were found between
groups at baseline evaluation. Likewise, there were no significant
differences between smokers and non-smokers after treatment (3
and 6 months follow-up) in their clinical symptomatology (accord-
ing to PANSS, HDRS and CGI-SCH), anthropometric measures and
heart rate.
Conclusions No significant differences were found in the clinical
symptoms after a period of nicotine abstinence. Therefore, cli-
nicians should motivate and help their patients to quit smoking
(CIBERSAM - FIS PI11/01891).
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW552
Functional outcome in psychosis is
better determined by negative
symptoms than cognitive impairment
A.M. Sánchez-Torres ∗, M.R. Elosúa ,
R. Lorente-Ome˜naca , L. Moreno-Izco , V. Peralta ,
M.J. Cuesta
1 Complejo Hospitalario de Navarra, Department of Psychiatry,
Pamplona, Spain
2 Universidad Nacional de Educación a Distancia UNED, Department
of Basic Psychology I, Madrid, Spain
3 IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
∗ Corresponding author.
Introduction Cognitive impairment is considered the best predic-
tor of functional outcome in psychosis. However, the nature of this
relationship still remains to be determined.
Objective To ascertain the relationship of negative symptoms and
cognitive impairment with functional outcome in psychosis.
Methods Ninety patients with a DSM-IV psychotic disorder diag-
nosis and 65 healthy controls were included in the study. We
assessed the predominant negative symptoms over the course of
illness with the Comprehensive Assessment of Symptoms and His-
tory (CASH). Functional outcome was assessed with the Specific
Levels of Functioning (SLOF). Cognition was assessed with a set
of neuropsychological tests, which were normalised to z-scores
(regarding controls’ performance). Then, a Global Cognition Index
(GCI) was obtained as a mean of the cognitive domains assessed:
processing speed, attention, verbal and visual memory, execu-
tive functions, working memory and social cognition. We divided
the sample in four groups, considering the presence/absence of
negative symptoms (cut-off point of 2 in the CASH), and the